Kanada-IPO: Delta 9 Bio

Der nächste Licenced Producer wagt den Sprung an die Börse: WINNIPEG, Nov. 1, 2017 /CNW/ - DELTA 9 CANNABIS INC. (TSXV: NINE) (formerly SVT Capital Corp.) (the "Company") is pleased to announce that it has completed its previously announced reverse takeover transaction (the "Transaction"), pursuant to which the Company has acquired all of the issued and outstanding shares of Delta 9 Bio-Tech Inc. ("Delta 9") by way of a three-cornered amalgamation among the Company, Delta 9 and 10240907 Canada Corp. ("Newco"). The Company expects to resume trading as a Tier 2 Industrial Issuer on the TSX Venture Exchange (the "TSXV") under the symbol "NINE" at market open on Monday, November  6, 2017.

In connection with the closing of the Transaction (the "Closing"), the Company:

  • changed its name to "Delta 9 Cannabis Inc.";
  • completed a brokered private placement offering (the "Concurrent Financing") of 8 million common shares in the capital of the Company (each, a "Share") at a price of $0.65 per Share for gross proceeds of $5.2 million;
  • appointed John William (Bill) Arbuthnot III, John William (John) Arbuthnot IV and Nitin Kaushal as directors, and Bill Arbuthnot, John Arbuthnot and Brent Bottomley as officers of the Company; and
  • retained Anthony Jackson as a director of the Company,

http://www.newswire.ca/news-releases/delta-9-announces-closing-of-reverse-takeover-and-concurrent-financing-654425333.html